TARGETED INHIBITION IN PEDIATRIC MET and ALK ALTERED PEDIATRIC HIGH GRADE GLIOMAS: OBJECTIVE RESPONSES FOLLOWED BY TREATMENT RESISTANCE

preprint OA: closed CC-BY-4.0
📄 Open PDF Full text JSON View at publisher

Abstract

Purpose: : Pediatric-type Diffuse High Grade Gliomas (pHGG) tend to have a dismal prognosis. Some of these gliomas feature alterations in genes such as ROS1, ALK, MET, and NTRK1-3. Despite advances in categorization and development of targeted agents, the therapeutic application of these agents in pHGG is still unclear. The aim of this study is to report the outcome of two patients with pHGG who received targeted agents with initial response followed by treatment resistance. Methods: : We present a retrospective case series of two patients diagnosed with pHGGs at Arkansas Children’s Hospital. Each diagnosis was determined based on histology, targeted tumor sequencing, and methylation profiling. Results: : Both patients were treated with targeted therapies (Cabozantinib for a MET fusion in patient 1 and Lorlatinib for an ALK fusion in patient 2) with an objective disease response in both patients. In both cases, relapse occurred while on targeted inhibition. Recurrent tumor sequencing for patient 2 revealed a MET copy gain suggesting the mechanism of resistance in this patient. Conclusion: : Pediatric high-grade gliomas with targetable alterations can show objective responses to pathway inhibition. Relapse after initial response may warrant additional surgical sample to identify new alterations which can lead to changes in therapy. Larger prospective cohorts are needed to study targeted agents in this population, and earlier integration of these agents may be beneficial.
Full text 2,664 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Purpose : Pediatric-type Diffuse High Grade Gliomas (pHGG) tend to have a dismal prognosis. Some of these gliomas feature alterations in genes such as ROS1, ALK, MET, and NTRK1-3. Despite advances in categorization and development of targeted agents, the therapeutic application of these agents in pHGG is still unclear. The aim of this study is to report the outcome of two patients with pHGG who received targeted agents with initial response followed by treatment resistance. Methods : We present a retrospective case series of two patients diagnosed with pHGGs at Arkansas Children’s Hospital. Each diagnosis was determined based on histology, targeted tumor sequencing, and methylation profiling. Results : Both patients were treated with targeted therapies (Cabozantinib for a MET fusion in patient 1 and Lorlatinib for an ALK fusion in patient 2) with an objective disease response in both patients. In both cases, relapse occurred while on targeted inhibition. Recurrent tumor sequencing for patient 2 revealed a MET copy gain suggesting the mechanism of resistance in this patient. Conclusion : Pediatric high-grade gliomas with targetable alterations can show objective responses to pathway inhibition. Relapse after initial response may warrant additional surgical sample to identify new alterations which can lead to changes in therapy. Larger prospective cohorts are needed to study targeted agents in this population, and earlier integration of these agents may be beneficial. Supplementary Material File (wilson pediatric high grade glioma case series.docx) - Download - 5.35 MB Information & Authors Information Version history Copyright This work is licensed under a Non Exclusive No Reuse License.

Keywords

Authors Metrics & Citations Metrics Article Usage 249views 117downloads Citations Download citation David Wilson, Sateesh Jayappa, Lora Parker, et al. TARGETED INHIBITION IN PEDIATRIC MET and ALK ALTERED PEDIATRIC HIGH GRADE GLIOMAS: OBJECTIVE RESPONSES FOLLOWED BY TREATMENT RESISTANCE. Authorea. 12 July 2025. DOI: https://doi.org/10.22541/au.175231445.55763704/v1 DOI: https://doi.org/10.22541/au.175231445.55763704/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-05-26T02:00:01.498150+00:00
License: CC-BY-4.0